Teva's Copaxone Trial Kicks Off Against Mylan, Sandoz

Law360, New York (September 7, 2011, 6:47 PM EDT) -- An attorney for Mylan Pharmaceuticals Inc. told a New York federal judge Wednesday that its generic version of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone doesn't infringe several Teva patents.

“They're different compositions, and they have different molecular ratios,” said Mylan attorney Shannon M. Bloodworth of Perkins Coie LLP in a standing-room-only courtroom in downtown Manhattan.

The remarks came during opening statements in a consolidated bench trial before U.S. District Judge Barbara S. Jones in two cases over Teva's allegations that Mylan and Novartis AG's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.